XECHEM INTERNATIONAL INC
NT 10-Q, 1996-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CELERITEK INC/CA, 10-Q, 1996-11-14
Next: QUINTILES TRANSNATIONAL CORP, 10-Q, 1996-11-14




                    U.S. SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549

                          NOTIFICATION OF LATE FILING

                                  FORM 12b-25

SEC File Number  0-23788                 Cusip Number  983895               

                                  [Check One]
     |_| Form 10-K|_| Form 20-F  |_| Form 11-K |X| Form 10-Q |_| Form N-SAR

                  For the Period Ended:        September 30, 1999           

                  [   ] Transition Report on Form 10-K
                  [   ] Transition Report on Form 20-F
                  [   ] Transition Report on Form 11-K
                  [   ] Transition Report on Form 10-Q
                  [   ] Transition Report on Form N-SAR
                  For the Transition Period Ended            


            Read Instructions [on back page] Before Preparing Form.
                             Please Print or Type
Nothing in this form shall be constructed to imply that the Commission has
verified any information contained herein
If the notification relates to a portion of the filing checked above,
 identify the Item[s] to which the notification relates:

                                                                            
PART I - REGISTRANT INFORMATION
Full Name of Registrant:Xechem International, Inc.
Former Name if Applicable:
Address of Principal Executive Office [Street and Number]:  100 Jersey Avenue 
- -B310 City, State and Zip Code:  New Brunswick, New Jersey 08901
PART II - RULES 12b-25[b] and [c]
If the subject report could not be filed without unreasonable effort or
 expense and the registrant seeks relief pursuant to Rule 12b-25[b], the
 following should be completed.
                          [Check box if appropriate]

          [a] The reasons described in reasonable detail in Part III of  this
           form could not be eliminated without unreasonable effort or expenses;
|X|       [b]     The subject annual report, semi-annual report, transition 
                  report on Form 10-K, Form 2-F, Form 11-K, Form N-SAR, or 
                  portion thereof , will be filed on or before the
                  fifteenth calendar day following the prescribed due date; 
                   or the subject quarterly report
                  or transition report on Form 10-Q, or portion thereof will
                   be filed on or before the fifth
                  calendar day following the prescribed due date; and

      [c] The accountant's statement or other exhibit required by
          Rule 12b-25[c] has been attached if applicable.


PART III - NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K,
 10-Q or N-SAR, or the transition report or portion thereof, could not
 be filed within the prescribed time period.  [Attach Extra Sheet if Needed]

PART IV - OTHER INFORMATION
    [1]  Name and telephone number of person to contact in regard to this
         notification

              Leonard A. Mudry                     908             247-3300   
                   [Name]                      [Area Code]      [Telephone No.]
 
    [2] Have all other periodic reports required under Section 13 or 15[d] 
        of the Securities and  Exchange Act of 1934 or Section 30 of the
        Investment Company Act of 1940 during the preceding 12 months
       [or for such shorter period that the registrant was required to file such
        reports] been filed?  If answer is no, identify report[s].
                                                        |X| Yes  |_|  No
                                                                                

    [3] Is it anticipated that any significant change in results of operations
    from the corresponding period for the last fiscal year will be reflected by
     the earnings statements to be included in the subject report or portion
   thereof?
                              |_|Yes  |X| No

      If so, attach an explanation of the anticipated change, both narratively
      and quantitatively, and, if appropriate, state the reasons why a
          reasonable estimate of the results cannot be made.

                             Xechem, International, Inc.                   
                  [Name of Registrant as Specified in Charter]

has caused this notification to be signed on its behalf by the undersigned
 thereunto duly authorized.

Date                                               By /s/ Leonard A. Mudry 
                                                         VP-Finance & Operations

INSTRUCTION:  The form may be signed by an executive officer of the registrant
 or by any other duly authorized representative.  The name and title of the
 person signing the form shall be typed or printed beneath the signature. 
 If the statement is signed on behalf of the registrant by an authorized
representative [other than an executive officer], evidence of the
 representative's authority to sign on behalf of the registrant shall be 
  filed with the form.

                                    ATTENTION
           Intentional misstatements or omissions of fact constitute
                Federal Criminal Violation  [See 18 U.S.C. 1001]

                              GENERAL INSTRUCTIONS

1.  This form is required by Rule 12b-25 [17 CFR 240.12b-25] of the General
    Rules and Regulations under the Securities Exchange Act of 1934.

2.  One signed original and four conformed copies of this form and amendments
    thereto must be completed and filed with the Securities and Exchange
     Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
     General Rules and Regulations under the Act.  The information  contained
     in or filed with the form will be made a matter of the public record in 
     the Commission files.

3.  A manually signed copy of the form and amendments thereto shall be filed
    with each national securities exchange on which any class of securities
     of the registrant is registered.

4   Amendments to the notifications must also be filed on form 12b-25, but
    need not restate information that has been correctly furnished.
    The form shall be clearly identified as an amendment notification.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission